The Medicare and Medicaid Promoting Interoperability (PI) Programs
Formerly Meaningful Use EHR Incentive Program
FCDS Participation in MIPS/MU 2020
Effective January 1st, 2020 the Florida Cancer Data System will no longer be participating in the CMS Interoperability Programs. Access to registration documentation and reporting status for the 2019 year will still be available through the IDEA System.
Physician reporting is still required by state statute. While we will no longer be accepting registration and/or submissions for the Interoperability programs in 2020, reporting to the cancer registry is still required by Florida state statute for providers in oncology, urology, hematology, and dermatology. We have established reporting mechanisms for these specialties and they will continue without change (e.g., Derm Abstract Module, electronic medical claims). For more information please follow this link: https://fcds.med.miami.edu/inc/physicians.shtml
As an alternative to MU/MIPS cancer reporting in Florida, there may be other available reporting options, such as the Center for Disease Control and Prevention's National Health Care Surveys
For questions please contact Monique Hernandez, Mhernandez5@med.miami.edu
Public Health Registry Reporting
The Florida Cancer Data System is currently receiving registrations and submissions of EHR cancer event reports to fulfill the Medicare and Medicaid Promoting Interoperability (PI) Programs. We are accepting both the 2014 and 2015 CERHT editions.
Beginning in performance year 2019, the 2015 CEHRT is required for participation in Medicare Merit-Based Incentive Payment System (MIPS)
More information on program requirements can be found at
Important Message: Participation in Meaningful Use Cancer reporting is voluntary. All targeted physicians who participate in Meaningful Use must continue to report cases through one of the Department of Health approved methods (claims, single entry, etc.) to meet state required reporting. Targeted physicians include oncology, dermatology, hematology, and urology practices.
Registration for Meaningful Use Cancer Reporting
Registration for existing users
Registration for new users
Registration for existing users
Registration for new users
FCDS Meaningful Use Readiness
In support of physician cancer reporting and Meaningful Use, the Florida Cancer Data System (FCDS) has implemented electronic reporting from certified electronic health record technology (CEHRT) systems as of January 1st, 2014 for Stage 2 using 2014 Edition CEHRT. Active engagement to the FCDS using this EHR reporting method will assist eligible professionals in receiving Medicare and Medicaid incentive funds for demonstration of Meaningful Use.
The FCDS also declares its readiness to the Stage 3 measures using 2015 Edition CEHRT. The FCDS plans to accept this criteria beginning on January 1, 2017. The Cancer Implementation Guide for ambulatory provider cancer reporting to state registries is updated to HL7 CDA (r) Release 2 Implementation Guide: Reporting to Public Health Cancer Registries from Ambulatory Healthcare Providers, Release 1, DSTU Release 1.1 - US Realm in the 2015 Edition CEHRT.
Included in the strategy for demonstrating Meaningful Use of an EHR system is the submission of cancer case reports. This objective applies only to Eligible Professionals (EP), also known as individual practitioners.
Meaningful Use Criteria for Cancer Reporting
Inclusions: Only EPs who diagnose or treat cancer patients may choose to report to the cancer registry under the Objective 10 and Measure 3 option: Public Health Reporting to a Specialized Registry. Additionally, only EPs who have the certified technology for cancer reporting (170.314(f)(5) and 170.314(f)(6)) are eligible for reporting to the FCDS.
Exclusions: EPs who do not diagnose or treat cancer patients are excluded from cancer reporting. Practices that diagnose and/or treat cancer but do not have the certified technology may claim an alternate exclusion in 2015.
If you are an EP who diagnoses and/or treats cancer patients but DOES NOT have the certified technology for cancer reporting, there is an option to report to the CDC's National Health Care Survey to fulfill this measure. Please visit their webpage for information on registration and reporting. www.cdc.gov/ehrmeaningfuluse/national_health_care_surveys.html
FCDS MU Guidance Documents
If you are interested in reporting to the FCDS using a certified EHR, or have questions, please send us an email.
MU FCDS Contacts
Monique N. Hernandez, PhD
Meaningful Use Manager
Sasha Raju, MBBS, MPH
Outreach and Quality Control Coordinator
Mark Rudolph, MS
Technical Contact and IT Manager
If you are interested in reporting to the FCDS using a certified EHR, or have questions, please send us an email
Onboarding Process for Cancer Messages
To meet the Meaningful Use (MU) cancer reporting objective, Eligible Professionals (EP) must register and complete all steps in the on-boarding process. Providers registered in the FCDS Meaningful Use Registration System will receive acknowledgement of the FCDS MU status they have achieved at the end of their reporting period. Statuses include Registered, Invited to Onboard, Testing and Validation, and In Production.
Click on the choices below to learn more.
1. Registration and Connectivity: Eligible Professional (EP) registers intent to submit cancer data for MU and
sets up transport option.
- - Register using the FCDS MU Registration System.
- - FCDS will provide an email confirmation to designated recipients of successful registration. A list of each EP
by name and NPI will be provided on the confirmation email for attestation purposes. Your MU status will be "Registered."
2. Message Structure Validation: EP submits cancer messages using defined structure for FDH staff to validate.
The message contains test data.
3. Message Content Validation: EP submits cancer messages using defined content standards for FCDS staff to
validate. Message contains actual patient data.
- - Submit messages that contain actual (production) data.
- - Incorporate feedback from FCDS to refine message content to meet MU and FCDS requirements.
4. Production: EP initiates ongoing submission of cancer data and participates in periodic quality
- - Initiate regular production transmission of cancer messages to FCDS. Your MU status will be updated from
"Testing and Validation" to "In Production."
- - Incorporate FCDS feedback as necessary to ensure quality of data.
- - FCDS will provide an e-mail communication acknowledging ongoing data transmission for the attestation period when
this step is completed.